Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study-Reference-Cited by-同舟云学术

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study

Published:2023-08 Issue:6 Volume:7 Page:102192
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Research and Practice in Thrombosis and Haemostasis

Author:

Dobesh Paul P.,Fermann Gregory J.,Christoph Mary J.,Koch Bruce,Lesén Eva,Chen Hungta,Lovelace Belinda,Dettling Theresa,Danese Mark,Ulloa Julie,Danese Sherry,Coleman Craig I.

Publisher

Elsevier BV

Subject

Hematology

Reference39 articles.

1. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee;Tomaselli;J Am Coll Cardiol,2020

2. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N Engl J Med,2011

3. Edoxaban versus warfarin in patients with atrial fibrillation;Giugliano;N Engl J Med,2013

4. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes;Hylek;J Am Coll Cardiol,2014

5. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban;Tamayo;Clin Cardiol,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Andexanet Alfa versus Four-Factor Prothrombin Complex Concentrate for the Reversal of Factor Xa (FXa) Inhibitor-Associated Intracranial Hemorrhage: A Systematic Review of Retrospective Studies;Journal of Clinical Medicine;2024-05-24

2. Reversal or Repletion Treatment Strategies and Outcomes of Patients With Major Bleeding Events Managed in the Emergency Department: Large Real-Life Investigation in the Northwestern Healthcare District of Tuscany;Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine;2024-05-22

3. Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?;Thrombosis Research;2024-05

4. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-05

5. Reply to “Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor–related major bleeding”;Research and Practice in Thrombosis and Haemostasis;2024-05